Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide.
Restrictive valvular heart disease (VHD) has recently been reported in Parkinson's disease (PD) patients treated with ergot dopamine agonists. The aim of the present study was to detect valvular changes in our patients and to investigate their relationship to long-term use of pergolide. We examined 90 patients (mean age 60.8 +/- SD 9.5 years) with PD, average duration 10.0 +/- 5.1 years. Mean pergolide dose was 2.93 +/- 0.75 (range 0.75 to 5) mg per day. 36 subjects (mean age 55.0 +/- 12.8 years) served as controls. All subjects underwent transthoracic echo-Doppler examination. Valve morphology was rated as normal, fibrotic, restrictive, or degenerative. In addition, the mitral tenting area (TA) and tenting distance (TD) were assessed. In 40 out of 90 (45%) PD patients and in 13 out of 36 (36%) controls, mild mitral regurgitation was observed. In 1 PD patient, a moderate mitral regurgitation was recorded. However, no case of restrictive VHD was found. Neither the TA (1.44 +/- 0.24 cm(2) vs 1.33 +/- 0.44 cm(2)) nor the TD (0.73 +/- 0.10 cm vs. 0.72 +/- 0.30 cm) differed from controls. There were no correlations between the current or cumulative dose of pergolide and TA or TD. Discrete fibrotic changes on valves were found in 10 out of 90 (11%) patients. Degenerative changes of valves were found in 11 (12%) patients and in 7 (19 %) controls. Thus in contrast to earlier findings of restrictive VHD in up to one-third of PD patients on pergolide, we did not find any significant heart disease. We only observed mild to moderate mitral regurgitation and clinically insignificant valvular fibrosis. A possible reason for such a discrepancy is that the daily doses of pergolide in our patients were inferior to those reported previously. In conclusion, the prevalence of restrictive VHD has been lower than expected in our patients with PD, probably in relation to moderate daily doses of pergolide.
Růzicka
Evzen
E
Department of Neurology, 1st School of Medicine Charles University, Katerinská 30, Prague, CZ-12000, The Czech Republic. eruzi@lf1.cuni.cz
Línková
Hana
H
Penicka
Martin
M
Ulmanová
Olga
O
Nováková
Lucie
L
Roth
Jan
J
D000368:Aged; D018491:Dopamine Agonists / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004452:Echocardiography / Q000379:methods; D005260:Female; D006349:Heart Valve Diseases / Q000139:chemically induced* / Q000453:epidemiology* / Q000473:pathology; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000187:drug effects / Q000503:physiopathology; D010300:Parkinson Disease / Q000188:drug therapy; D010479:Pergolide / Q000009:adverse effects*
D018491:Dopamine Agonists; D010479:Pergolide
J Am Soc Echocardiogr. 1990 Jan-Feb;3(1):54-63
2310593
Mov Disord. 2006 Aug;21(8):1261-4
16685692
Mov Disord. 2006 Aug;21(8):1109-13
16622856
Mov Disord. 2004 Jun;19(6):699-704
15197712
N Engl J Med. 2007 Jan 4;356(1):39-46
17202454
Mayo Clin Proc. 2002 Dec;77(12):1280-6
12479512
Am J Cardiol. 1999 Mar 15;83(6):897-902
10190406
Mov Disord. 2004 Jun;19(6):656-62
15197703
Lancet. 2004 Apr 10;363(9416):1179-83
15081648
Mov Disord. 2006 Apr;21(4):586-7
16482572
Neurology. 2004 Jul 27;63(2):301-4
15277624
Mayo Clin Proc. 2003 Jun;78(6):730-1
12934784
J Neurol Neurosurg Psychiatry. 1999 Jan;66(1):79-81
9886458
Mov Disord. 2004 Dec;19(12):1524-5
15515031
Mayo Clin Proc. 2005 Aug;80(8):1016-20
16092580
Cas Lek Cesk. 2005;144(2):123-6
15807300